Campaign News

Unravelling the genetics of stuttering

VIVA! Communications is today working with researchers from the NHMRC Centre of Research Excellence in Speech and Language to call for 3,000 Australians aged seven and above with experience of stuttering (past or present) to volunteer for the nation’s largest ever ‘Genetics of Stuttering Study’. The study aims to pinpoint the genes that predispose individuals to…

Read More

Australia sees launch of world-first Olive Wellness Institute

A new research review confirming the ‘health and prolongevity effects’ of the traditional extra virgin olive oil (EVOO)-containing Mediterranean diet coincides with today’s launch of the world’s-first online science repository on the health benefits of olive products. Conducted by US and Italian geriatric and nutritional research scientists, the Health Benefits of the Mediterranean Diet: Metabolic…

Read More

The VIVA! team is turning to olive leaf extract this autumn

As February draws to a close, the cooler days will inevitably begin to outnumber the warmer ones. Ushered in alongside the chilly temperatures will be viruses such as the flu and rhinovirus (the common cold). At VIVA! we’re not only dedicated to inspiring healthy lifestyles through our PR work in the general community, but we’re…

Read More

MedReleaf Australia enters local medicinal cannabis market

An Australian joint venture company associated with one of Canada’s leading licensed producers of medical cannabis (MedReleaf Corp) has entered the local Australian medicinal cannabis market after securing ‘cultivation and production’ and ‘import’ licenses from the Federal Government’s Office of Drug Control (ODC). MedReleaf Australia will import medicinal cannabis from MedReleaf Corp (which has a…

Read More

Government adds $142 million in medicines to PBS

As of July 1, 2017, the Federal Government has made AUD$142 million in new medicine listings to the Pharmaceutical Benefits Scheme (PBS), in a bid to make more medicines affordable to all Australians. Among the new listings, the PBS will fund access to vorinostat to treat patients living a subtype of blood cancer, non-Hodgkin’s lymphoma called…

Read More